Inhibition of ERK1/2 activity by the MEK1/2 inhibitor AZD6244 (ARRY-142886) induces human multiple myeloma cell apoptosis in the bone marrow microenvironment: A new therapeutic strategy for MM.

被引：2
|
作者：
Tai, Yu-Tzu [1 ]
Li, Xian-Feng [1 ]
Breitkreutz, Iris [1 ]
Song, Weihua [1 ]
Burger, Peter [1 ]
Rumizen, Matthew [1 ]
Hideshima, Teru [1 ]
Podar, Klaus [1 ]
Ghobrial, Irene [1 ]
Schlossman, Robert [1 ]
Richardson, Paul [1 ]
Munshi, Nikhil C. [1 ]
Anderson, Kenneth C. [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.3460.3460
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3460
引用
收藏
页码：987A / 987A
页数：1
相关论文
共 36 条
  • [21] AZD6244 (ARRY-142886), a potent and highly selective MEK1/2 inhibitor, demonstrates anti-HIF properties, and increases the therapeutic response in a lung tumor xenograft model when combined with radiotherapy
    Shannon, Aoife M.
    Telferi, Brian A.
    Babur, Muhammed
    Smith, Paul D.
    Logie, Armelle
    Wilkinson, Robert W.
    Stratford, Ian J.
    Williams, Kaye J.
    Wedge, Steve R.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3414S - 3415S
  • [22] The MEK1/2 inhibitor selumetinib (AZD6244; ARRY-142886) appears as an efficient targeted therapy when used in an adjuvant setting in patient-derived xenografts of uveal melanoma
    Diallo, B.
    Massonnet, G.
    El-Botty, R.
    Raymondie, C.
    Howes, C.
    Wilson, J.
    Smith, A.
    Roman-Roman, S.
    Smith, P.
    Davies, E.
    Decaudin, D.
    Nemati, F.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S132 - S132
  • [23] The MEK1/2 inhibitor selumetinib (AZD6244; ARRY-142886) appears as an efficient targeted therapy when used in an adjuvant setting in patient-derived xenografts of uveal melanoma
    Diallo, Bere
    Massonnet, Gerald
    El-Botty, Rania
    Raymondie, Chloe
    Carita, Guillaume
    -Roman, Sergio Roman
    Smith, Paul
    Davies, Emma
    Decaudin, Didier
    Nemati, Fariba
    CANCER RESEARCH, 2016, 76
  • [24] Phase II Study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).
    Gross, Andrea M.
    Baldwin, Andrea
    Dombi, Eva
    Wolters, Pamela
    Whitcomb, Patricia
    Holmblad, Marielle
    Martin, Staci
    Fisher, Michael J.
    Kim, AeRang
    Weiss, Brian D.
    Paul, Scott M.
    Clapp, Wade
    Farrell, Kathleen
    Smith, Michaele
    Fontana, Joseph
    Brofferio, Alessandra
    Steinberg, Seth M.
    Doyle, Laurence A.
    Widemann, Brigitte C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [25] SPRINT: PHASE II STUDY OF THE MEK 1/2 INHIBITOR SELUMETINIB (AZD6244, ARRY-142886) IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 (NF1) AND INOPERABLE PLEXIFORM NEUROFIBROMAS (PN)
    Gross, Andrea
    Wolters, Pamela
    Baldwin, Andrea
    Dombi, Eva
    Fisher, Michael J.
    Weiss, Brian
    Kim, AeRang
    Blakeley, Jaishri
    Whitcomb, Patricia
    Holmblad, Marielle
    Maritin, Staci
    Roderick, Marie Claire
    Paul, Scott M.
    Therrien, Janet
    Heisey, Kara
    Doyle, Austin
    Smith, Malcolm
    Glod, John
    Steinberg, Seth
    Widemann, Brigitte C.
    NEURO-ONCOLOGY, 2018, 20 : 143 - 144
  • [26] A Phase II Study of the MEK 1/2 Inhibitor AZD6244 (Selumetinib, ARRY-142866) in Relapsed or Refractory Multiple Myeloma
    Holkova, Beata
    Badros, Ashraf Z.
    Geller, Robert
    Voorhees, Peter M.
    Zingone, Adriana
    Korde, Neha
    Lin, Hui-Yi
    Tombes, Mary Beth
    Shrader, Ellen
    Sankala, Heidi
    Kmieciak, Maciej
    Roberts, John D.
    Sullivan, Daniel
    Landgren, Ola
    Grant, Steven
    BLOOD, 2011, 118 (21) : 1264 - 1264
  • [27] SPRINT: Phase II study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).
    Gross, Andrea M.
    Wolters, Pamela
    Baldwin, Andrea
    Dombi, Eva
    Fisher, Michael J.
    Weiss, Brian D.
    Kim, AeRang
    Blakeley, Jaishri O'Neill
    Whitcomb, Patricia
    Holmblad, Marielle
    Martin, Staci
    Roderick, Marie Claire
    Paul, Scott M.
    Therrien, Janet
    Heisey, Kara
    Doyle, Austin
    Smith, Malcolm A.
    Glod, John
    Steinberg, Seth M.
    Widemann, Brigitte C.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [28] The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer
    Banerji, Udai
    Camidge, D. Ross
    Verheul, Henk M. W.
    Agarwal, Roshan
    Sarker, Debashis
    Kaye, Stan B.
    Desar, Ingrid M. E.
    Timmer-Bonte, Johanna N. H.
    Eckhardt, S. Gail
    Lewis, Karl D.
    Brown, Kathryn H.
    Cantarini, Mireille V.
    Morris, Clive
    George, Sarah M. A.
    Smith, Paul D.
    van Herpen, Carla M. L.
    CLINICAL CANCER RESEARCH, 2010, 16 (05) : 1613 - 1623
  • [29] Phase II trial of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886 Hydrogen Sulfate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).
    Coyne, Geraldine Helen O'Sullivan
    Gross, Andrea M.
    Dombi, Eva
    Tibery, Cecilia
    Carbonell, Amanda
    Takebe, Naoko
    Derdak, Joanne
    Pichard, Dominique
    Srivastava, Apurva K.
    Herrick, William
    Parchment, Ralph E.
    Martin, Staci
    Wolters, Pamela
    Whitcomb, Patricia
    Rubinstein, Lawrence
    Doroshow, James H.
    Chen, Alice P.
    Widemann, Brigitte C.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [30] Direct inhibition of ERK1/2 by VTX-11e leads to increased induction of apoptosis in a subset of pancreatic cancer cell lines as compared to MEK1/2 inhibition by selumetinib (AZD6244)
    Miermont, Anne M.
    Pflicke, Holger
    Guan, Hannah
    Chinnasamy, Harshini
    Thomas, Craig
    Rudloff, Udo
    CANCER RESEARCH, 2013, 73 (08)
1234